A Hybrid Drug paradigm. Entity uses AI to reveal and map the unified dimension of consciousness—transforming altered states into objective landscapes for universal human empowerment and deeper healing.
The FDA just received a presidential executive order to fast-track psychedelic therapy. Every clinic that opens needs an intelligent system to make sessions work.
We are developing that system.
Psychedelic experiences are not totally subjective hallucinations. They form a shared, objective landscape—including entity encounters and out-of-body experiences. Our Hybrid Drug integrates advanced AI biofeedback to map this unified dimension, providing the grounds for profound cognitive and psychological empowerment for every person, regardless of ailment.
View Scientific ArchitectureTo illuminate the shared landscape of the human mind.
To map the unified dimension of altered states, providing universal psychological empowerment through Hybrid Drug technology.
Dramatically enhance the capabilities of the human therapist or caregiver during sessions.
Eventually replace the human therapist totally, acting as an autonomous guide.
Map the common landscape of altered states to unlock deeper healing and cognitive potential for every person, not just the clinically ill.
FDA Commissioner Dr. Marty Makary and HHS leadership have initiated priority review pathways, dramatically shortening commercialization timelines for breakthrough psychedelic therapies.
Read on FDA.gov →Following recent federal executive action, the psychedelic medicine sector has seen heightened investor interest and significant market rallies, with projections pointing to a $15B market by 2035.
Read on Forbes →The industry is embracing 'Hybrid Drugs'—a novel Drug-SaMD combination that pairs traditional pharmacological compounds with adaptive AI digital protocols for synergistic clinical outcomes.
Read on Fierce Biotech →Biotech companies are leveraging LLMs to analyze tens of thousands of trip reports, classifying altered states of consciousness to drive next-generation precision neurotherapeutics.
Read on STAT News →The FDA has begun issuing national priority vouchers to companies studying psychedelic therapies, signaling a major transition to fast-track clinical research and right-to-try access.
Read on Bloomberg →With multiple late-stage Phase 3 trials underway for treatment-resistant depression and PTSD, analysts cite 2026 as a critical tipping point for impending FDA approvals.
Read on Investing.com →AI in psychedelic therapy involves using advanced language models and biofeedback systems to create a responsive, safe, and guided environment for patients undergoing psychedelic treatments. The AI Therapeutic Engine reads physiological data in real-time to adjust lighting, sound, and interactions, enhancing the therapeutic outcome.
Psychedelic integration software uses digital biofeedback to track the patient's state vector (EEG, HRV). By interpreting this data, the system actively synchronizes digital environments (like soundscapes) with the patient's physiological state, ensuring deeper emotional breakthroughs and reducing anxiety.
As psychedelic medicine scales, ensuring consistent, high-quality care across every clinic is vital. Our Entity - AI Therapeutic Engine serves as a digital guide, providing a standardized yet highly personalized AI co-presence that supports the practitioner and maximizes the patient's healing potential.